Figure 2
Figure 2. Antigen-induced neutrophilic airway inflammation in OTII mice. Wild-type (WT) or OTII mice were treated with 50 μg of OVA or KLH in PBS, or PBS alone intranasally for 3 days (once per day). Data in panels A-C, E are the average + SD of results pooled from 2 independent experiments, each of which gave similar results (n = 7-10). (A) Cells in BALF were quantified 24 hours after the last inhalation of OVA, KLH, or PBS. *P < .01; †P < .01 versus corresponding values for PBS-, OVA-, or KLH-treated wild-type mice and PBS- or KLH-treated OTII mice, respectively. (B) OVA-specific IgG1 and IgE in sera collected from mice in panel A 24 hours after the last OVA or PBS inhalation. (C) Airway responses (Penh and lung resistance [RL]) to methacholine were assessed 24 hours after the last inhalation of OVA, KLH, or PBS, as in panel A; BL indicates baseline. *P < .05 versus corresponding values for each of the other groups (by analysis of variance). (D) BALF cells pooled from 20 OTII mice 24 hours after the last OVA inhalation were stimulated with PMA plus ionomycin in the presence of monensin, and then the intracellular cytokine profiles of CD4+ T cells (% positive cells shown in the figure) were determined by FACS. Results shown are representative of those obtained in 2 independent experiments, each of which gave similar results. (E) Cytokine levels in BALF obtained 24 hours after the last OVA or PBS inhalation in mice shown in panel A. *P < .01; †P < .01 versus corresponding values for PBS- or OVA-treated wild-type mice and PBS-treated OTII mice, respectively.

Antigen-induced neutrophilic airway inflammation in OTII mice. Wild-type (WT) or OTII mice were treated with 50 μg of OVA or KLH in PBS, or PBS alone intranasally for 3 days (once per day). Data in panels A-C, E are the average + SD of results pooled from 2 independent experiments, each of which gave similar results (n = 7-10). (A) Cells in BALF were quantified 24 hours after the last inhalation of OVA, KLH, or PBS. *P < .01; †P < .01 versus corresponding values for PBS-, OVA-, or KLH-treated wild-type mice and PBS- or KLH-treated OTII mice, respectively. (B) OVA-specific IgG1 and IgE in sera collected from mice in panel A 24 hours after the last OVA or PBS inhalation. (C) Airway responses (Penh and lung resistance [RL]) to methacholine were assessed 24 hours after the last inhalation of OVA, KLH, or PBS, as in panel A; BL indicates baseline. *P < .05 versus corresponding values for each of the other groups (by analysis of variance). (D) BALF cells pooled from 20 OTII mice 24 hours after the last OVA inhalation were stimulated with PMA plus ionomycin in the presence of monensin, and then the intracellular cytokine profiles of CD4+ T cells (% positive cells shown in the figure) were determined by FACS. Results shown are representative of those obtained in 2 independent experiments, each of which gave similar results. (E) Cytokine levels in BALF obtained 24 hours after the last OVA or PBS inhalation in mice shown in panel A. *P < .01; †P < .01 versus corresponding values for PBS- or OVA-treated wild-type mice and PBS-treated OTII mice, respectively.

Close Modal

or Create an Account

Close Modal
Close Modal